سولیفناسین (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "سولیفناسین" in Persian language version.

refsWebsite

Global rank Persian rank

2jst.go.jp

1,903^rd place

7,888^th place

2nih.gov

4^th place

5^th place

1drugs.com

399^th place

104^th place

1ubc.ca

1,997^th place

2,449^th place

1web.archive.org

1^st place

1medicaid.gov

low place

1clincalc.com

3,912^th place

779^th place

1merck.com

6,464^th place

3,785^th place

1medicines.org.uk

3,823^rd place

1,188^th place

1who.int

195^th place

129^th place

1doi.org

2^nd place

clincalc.com

"The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.

doi.org

Ko Y, Malone DC, Armstrong EP (Dec 2006). "Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder". Pharmacotherapy. 26 (12): 1694–702. doi:10.1592/phco.26.12.1694. PMID 17125433.

drugs.com

"Solifenacin Succinate Monograph for Professionals". Drugs.com (به انگلیسی). American Society of Health-System Pharmacists.

jst.go.jp

jstage.jst.go.jp

Kobayashi, S.; et al. (July 2001). "Effects of YM905, a Novel Muscarinic M3-Receptor Antagonist, on Experimental Models of Bowel Dysfunction In Vivo". Jpn. J. Pharmacol. 86 (3): 281–288. PMID 11488427.
Ko Y, Malone DC, Armstrong EP (Dec 2006). "Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder". Pharmacotherapy. 26 (12): 1694–702. doi:10.1592/phco.26.12.1694. PMID 17125433.

medicaid.gov

data.medicaid.gov

"NADAC as of 2019-02-27". Cente rs for Medicare and Medicaid Services (به انگلیسی). Archived from the original on 6 March 2019. Retrieved 3 March 2019. {{cite web}}: line feed character in |website= at position 6 (help)

medicines.org.uk

"Vesicare 5mg & 10mg film-coated tablets". eMC. Retrieved 13 December 2015.

merck.com

Lexi-Comp (December 2009). "Solifenacin". The Merck Manual Professional. Retrieved 10 June 2011.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kobayashi, S.; et al. (July 2001). "Effects of YM905, a Novel Muscarinic M3-Receptor Antagonist, on Experimental Models of Bowel Dysfunction In Vivo". Jpn. J. Pharmacol. 86 (3): 281–288. PMID 11488427.
Ko Y, Malone DC, Armstrong EP (Dec 2006). "Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder". Pharmacotherapy. 26 (12): 1694–702. doi:10.1592/phco.26.12.1694. PMID 17125433.

ubc.ca

ti.ubc.ca

"[93] Are claims for newer drugs for overactive bladder warranted?". Therapeutics Initiative (به انگلیسی). 22 April 2015. Retrieved 17 March 2019.

web.archive.org

"NADAC as of 2019-02-27". Cente rs for Medicare and Medicaid Services (به انگلیسی). Archived from the original on 6 March 2019. Retrieved 3 March 2019. {{cite web}}: line feed character in |website= at position 6 (help)

who.int

"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 47" (PDF). World Health Organization. p. 106. Retrieved 5 February 2017.